Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 1/2a dose-escalation study of IPL344 in amyotrophic lateral sclerosis
MOH_2018-06-07_002434Phase 2Active, not recruiting
- Sponsor
- Immunity Pharma
- Start
- Jun 2018
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of IPL344 in amyotrophic lateral sclerosis (ALS), sponsored by Immunity Pharma. Primary endpoints: Safety and tolerability of IPL344 and Pharmacokinetics of IPL344. Started Jun 2018; status: active, not recruiting.
02
Drugs
IPL344
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on MOH_2018-06-07_002434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-06-07_002434.